EFNS guidelines on diagnosis and treatment of primary dystonias

European Journal of Neurology

Volumn 18, Issue 1, 2011, Pages 5-18

  Albanese, A ^a,b   Asmus, F ^c   Bhatia, K P ^d   Elia, A E ^a,b   Elibol, B ^e   Filippini, G ^a   Gasser, T ^c   Krauss, J K ^f   Nardocci, N ^a   Newton, A ^g   Valls Sole J ^h  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HACETTEPE UNIVERSITY   (Turkey)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g European Dystonia Federation   (Belgium)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

Classification; Diagnosis; Dystonia; Genetics; Guidelines; Treatment

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; DENERVATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSTONIA; EMBASE; EMTREE THESAURUS; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MEDICAL SPECIALIST; MEDLINE; MESH HEADING; MUSCLE RESECTION; MYOCLONUS; MYOTOMY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; PATIENT ASSESSMENT; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIMARY DYSTONIA; PRIORITY JOURNAL; RATING SCALE; SYSTEMATIC REVIEW; VALIDATION PROCESS;

BOTULINUM TOXINS; DEEP BRAIN STIMULATION; DYSTONIA; DYSTONIC DISORDERS; GLOBUS PALLIDUS; HUMANS; MOLECULAR CHAPERONES;

EID: 78650149431     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03042.x     Document Type: Article

References (173)

1. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S eds. Movement disorders 2. London: Butterworths, 1987: 332-358.
2. Fahn S, Bressman S, Marsden CD. Classification of dystonia. Adv Neurol 1998; 78: 1-10.
3. Lalli S, Albanese A. The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord 2010; in press.
4. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22: 2210-2215.
5. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
6. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13: 433-444.
7. Ludlow CL, Adler CH, Berke GS, et al. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg 2008; 139: 495-505.
8. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008; 71: 1275-82.
9. Albanese A, Lalli S. Is this dystonia? Mov Disord 2009; 24: 1725-1731.
10. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73-77.
11. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T. Rating scales for dystonia: a multicenter assessment. Mov Disord 2003; 18: 303-312.
12. Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT. Patient-based outcomes of cervical dystonia: a review of rating scales. Mov Disord 2004; 19: 1054-1059.
13. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M eds. Therapy with botulinum toxin. New York, NY: Marcel Dekker, 1994: 211-237.
14. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; 2: 245-247.
15. O'Brien C, Brashear A, Cullis P, et al. Cervical dystonia severity scale reliability study. Mov Disord 2001; 16: 1086-1090.
16. Lim VK. Health related quality of life in patients with dystonia and their caregivers in New Zealand and Australia. Mov Disord 2007; 22: 998-1003.
17. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40-48.
18. Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009; 41: 286-288.
19. Muller U. The monogenic primary dystonias. Brain 2009; 132: 2005-2025.
20. Calakos N, Patel V, Gottron M, et al. Functional evidence implicating a novel TOR1A mutation in idiopathic, late-onset focal dystonia. J Med Genet 2009; in press.
21. Bressman SB, Raymond D, Wendt K, et al. Diagnostic criteria for dystonia in DYT1 families. Neurology 2002; 59: 1780-1782.
22. Zirn B, Grundmann K, Huppke P, et al. Novel TOR1A mutation p.Arg288Gln in early-onset dystonia (DYT1). J Neurol Neurosurg Psychiatry 2008; 79: 1327-1330.
23. Edwards M, Wood N, Bhatia K. Unusual phenotypes in DYT1 dystonia: a report of five cases and a review of the literature. Mov Disord 2003; 18: 706-711.
24. Gambarin M, Valente EM, Liberini P, et al. Atypical phenotypes and clinical variability in a large Italian family with DYT1-primary torsion dystonia. Mov Disord 2006; 21: 1782-1784.
25. Valente EM, Warner TT, Jarman PR, et al. The role of DYT1 in primary torsion dystonia in Europe. Brain 1998; 121: 2335-2339.
26. Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000; 54: 1746-1752.
27. Fasano A, Nardocci N, Elia AE, Zorzi G, Bentivoglio AR, Albanese A. Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. Mov Disord 2006; 21: 1411-1418.
28. Djarmati A, Schneider SA, Lohmann K, et al. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009; 8: 447-452.
29. Bressman SB, Raymond D, Fuchs T, Heiman GA, Ozelius LJ, Saunders-Pullman R. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 2009; 8: 441-446.
30. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976; 14: 215-233.
31. Trender-Gerhard I, Sweeney MG, Schwingenschuh P, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80: 839-845.
32. Bandmann O, Wood NW. Dopa-responsive dystonia. The story so far. Neuropediatrics 2002; 33: 1-5.
33. Hagenah J, Saunders-Pullman R, Hedrich K, et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 2005; 64: 908-811.
34. Steinberger D, Trubenbach J, Zirn B, Leube B, Wildhardt G, Muller U. Utility of MLPA in deletion analysis of GCH1 in dopa-responsive dystonia. Neurogenetics 2007; 8: 51-55.
35. Zirn B, Steinberger D, Troidl C, et al. Frequency of GCH1 deletions in Dopa-responsive dystonia. J Neurol Neurosurg Psychiatry 2008; 79: 183-186.
36. Clot F, Grabli D, Cazeneuve C, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 2009; 132: 1753-1763.
37. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations. Brain 2000; 123: 1112-1121.
38. Jeon BS, Jeong JM, Park SS, et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998; 43: 792-800.
39. Verbeek MM, Steenbergen-Spanjers GC, Willemsen MA, et al. Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Ann Neurol 2007; 62: 422-426.
40. Robinson R, McCarthy GT, Bandmann O, Dobbie M, Surtees R, Wood NW. GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. J Neurol Neurosurg Psychiatry 1999; 66: 86-89.
41. Bandmann O, Goertz M, Zschocke J, et al. The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 2003; 60: 700-702.
42. Hyland K, Fryburg JS, Wilson WG, et al. Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology 1997; 48: 1290-1297.
43. Hyland K, Nygaard TG, Trugman JM, Swoboda KJ, Arnold LA, Sparagana SP. Oral phenylalanine loading profiles in symptomatic and asymptomatic gene carriers with dopa-responsive dystonia due to dominantly inherited GTP cyclohydrolase deficiency. J Inherit Metab Dis 1999; 22: 213-215.
44. Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol 2004; 94: 113-119.
45. Foncke EM, Gerrits MC, van RF, et al. Distal myoclonus and late onset in a large Dutch family with myoclonus-dystonia. Neurology 2006; 67: 1677-1680.
46. Asmus F, Langseth A, Doherty E, et al. "Jerky" dystonia in children: spectrum of phenotypes and genetic testing. Mov Disord 2009; 24: 702-709.
47. Vidailhet M, Tassin J, Durif F, et al. A major locus for several phenotypes of myoclonus--dystonia on chromosome 7q. Neurology 2001; 56: 1213-1216.
48. Tezenas du Montcel S, Clot F, Vidailhet M, et al. Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet 2006; 43: 394-400.
49. Ritz K, Gerrits MC, Foncke EM, et al. Myoclonus-dystonia: clinical and genetic evaluation of a large cohort. J Neurol Neurosurg Psychiatry 2009; 80: 653-658.
50. Grunewald A, Djarmati A, Lohmann-Hedrich K, et al. Myoclonus-dystonia: significance of large SGCE deletions. Hum Mutat 2008; 29: 331-332.
51. Valente EM, Edwards MJ, Mir P, et al. The epsilon-sarcoglycan gene in myoclonic syndromes. Neurology 2005; 64: 737-739.
52. Klein C, Schilling K, Saunders-Pullman RJ, et al. A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. Am J Hum Genet 2000; 67: 1314-1319.
53. Leung JC, Klein C, Friedman J, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 2001; 3: 133-143.
54. Asmus F, Zimprich A, Tezenas du MS, et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002; 52: 489-492.
55. Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol 2005; 58: 792-797.
56. Han F, Racacho L, Yang H, et al. Large deletions account for an increasing number of mutations in SGCE. Mov Disord 2008; 23: 456-460.
57. Asmus F, Hjermind LE, Dupont E, et al. Genomic deletion size at the epsilon-sarcoglycan locus determines the clinical phenotype. Brain 2007; 130: 2736-2745.
58. Bonnet C, Gregoire MJ, Vibert M, Raffo E, Leheup B, Jonveaux P. Cryptic 7q21 and 9p23 deletions in a patient with apparently balanced de novo reciprocal translocation t(7;9)(q21;p23) associated with a dystonia-plus syndrome: paternal deletion of the epsilon-sarcoglycan (SGCE) gene. J Hum Genet 2008; 53: 876-885.
59. Guettard E, Portnoi MF, Lohmann-Hedrich K, et al. Myoclonus-dystonia due to maternal uniparental disomy. Arch Neurol 2008; 65: 1380-1385.
60. Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia-parkinsonism. Neurology 1993; 43: 2596-2602.
61. Brashear A, Dobyns WB, de Carvalho Aguiar P, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007; 130: 828-835.
62. Camargos S, Scholz S, Simon-Sanchez J, et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008; 7: 207-215.
63. Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol 2004; 61: 1025-1029.
64. Lee HY, Xu Y, Huang Y, et al. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet 2004; 13: 3161-3170.
65. Chen DH, Matsushita M, Rainier S, et al. Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds. Arch Neurol 2005; 62: 597-600.
66. Bruno MK, Lee HY, Auburger GW, et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology 2007; 68: 1782-1789.
67. Weber YG, Storch A, Wuttke TV, et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest 2008; 118: 2157-2168.
68. Suls A, Dedeken P, Goffin K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 2008; 131: 1831-1844.
69. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995; 57: 1233-1241.
70. Klein C, Friedman J, Bressman S, et al. Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects. Genet Test 1999; 3: 323-328.
71. Tinazzi M, Squintani G, Berardelli A. Does neurophysiological testing provide the information we need to improve the clinical management of primary dystonia? Clin Neurophysiol 2009; 120: 1424-1432.
72. Brighina F, Romano M, Giglia G, et al. Effects of cerebellar TMS on motor cortex of patients with focal dystonia: a preliminary report. Exp Brain Res 2009; 192: 651-656.
73. Teo JT, van De Warrenburg BP, Schneider SA, Rothwell JC, Bhatia KP. Neurophysiological evidence for cerebellar dysfunction in primary focal dystonia. J Neurol Neurosurg Psychiatry 2009; 80: 80-83.
74. Marelli C, Canafoglia L, Zibordi F, et al. A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord 2008; 23: 2041-2048.
75. Edwards MJ, Huang YZ, Mir P, Rothwell JC, Bhatia KP. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov Disord 2006; 21: 2181-2186.
76. Murase N, Kaji R, Shimazu H, et al. Abnormal premovement gating of somatosensory input in writer's cramp. Brain 2000; 123: 1813-1829.
77. Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol 2004; 56: 595-599.
78. Fiorio M, Gambarin M, Valente EM, et al. Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? Brain 2007; 130: 134-142.
79. Tamura Y, Ueki Y, Lin P, et al. Disordered plasticity in the primary somatosensory cortex in focal hand dystonia. Brain 2009; 132: 749-755.
80. Contarino MF, Kruisdijk JJ, Koster L, Ongerboer de Visser BW, Speelman JD, Koelman JH. Sensory integration in writer's cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol 2007; 118: 2195-2206.
81. Lourenco G, Meunier S, Vidailhet M, Simonetta-Moreau M. Impaired modulation of motor cortex excitability by homonymous and heteronymous muscle afferents in focal hand dystonia. Mov Disord 2007; 22: 523-527.
82. Scontrini A, Conte A, Defazio G, et al. Somatosensory temporal discrimination in patients with primary focal dystonia. J Neurol Neurosurg Psychiatry 2009; 80: 1315-1319.
83. Quartarone A, Morgante F, Sant'angelo A, et al. Abnormal plasticity of sensorimotor circuits extends beyond the affected body part in focal dystonia. J Neurol Neurosurg Psychiatry 2008; 79: 985-990.
84. Espay AJ, Morgante F, Purzner J, Gunraj CA, Lang AE, Chen R. Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol 2006; 59: 825-834.
85. Avanzino L, Martino D, van De Warrenburg BP, et al. Cortical excitability is abnormal in patients with the "fixed dystonia" syndrome. Mov Disord 2008; 23: 646-652.
86. Fabbrini G, Pantano P, Totaro P, et al. Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm. Eur J Neurol 2008; 15: 185-189.
87. Carbon M, Kingsley PB, Tang C, Bressman S, Eidelberg D. Microstructural white matter changes in primary torsion dystonia. Mov Disord 2008; 23: 234-239.
88. Delmaire C, Vidailhet M, Wassermann D, et al. Diffusion abnormalities in the primary sensorimotor pathways in writer's cramp. Arch Neurol 2009; 66: 502-508.
89. Bonilha L, de Vries PM, Vincent DJ, et al. Structural white matter abnormalities in patients with idiopathic dystonia. Mov Disord 2007; 22: 1110-1116.
90. Schmidt KE, Linden DE, Goebel R, Zanella FE, Lanfermann H, Zubcov AA. Striatal activation during blepharospasm revealed by fMRI. Neurology 2003; 60: 1738-1743.
91. Preibisch C, Berg D, Hofmann E, Solymosi L, Naumann M. Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study. J Neurol 2001; 248: 10-17.
92. Oga T, Honda M, Toma K, et al. Abnormal cortical mechanisms of voluntary muscle relaxation in patients with writer's cramp: an fMRI study. Brain 2002; 125: 895-903.
93. Peller M, Zeuner KE, Munchau A, et al. The basal ganglia are hyperactive during the discrimination of tactile stimuli in writer's cramp. Brain 2006; 129: 2697-2708.
94. Butterworth S, Francis S, Kelly E, McGlone F, Bowtell R, Sawle GV. Abnormal cortical sensory activation in dystonia: an fMRI study. Mov Disord 2003; 18: 673-682.
95. Obermann M, Yaldizli O, De GA, et al. Increased basal-ganglia activation performing a non-dystonia-related task in focal dystonia. Eur J Neurol 2008; 15: 831-838.
96. Obermann M, Yaldizli O, De GA, et al. Morphometric changes of sensorimotor structures in focal dystonia. Mov Disord 2007; 22: 1117-1123.
97. Draganski B, Thun-Hohenstein C, Bogdahn U, Winkler J, May A. "Motor circuit" gray matter changes in idiopathic cervical dystonia. Neurology 2003; 61: 1228-1231.
98. Garraux G, Bauer A, Hanakawa T, Wu T, Kansaku K, Hallett M. Changes in brain anatomy in focal hand dystonia. Ann Neurol 2004; 55: 736-739.
99. Egger K, Mueller J, Schocke M, et al. Voxel based morphometry reveals specific gray matter changes in primary dystonia. Mov Disord 2007; 22: 1538-1542.
100. Delmaire C, Vidailhet M, Elbaz A, et al. Structural abnormalities in the cerebellum and sensorimotor circuit in writer's cramp. Neurology 2007; 69: 376-380.
101. Draganski B, Schneider SA, Fiorio M, et al. Genotype-phenotype interactions in primary dystonias revealed by differential changes in brain structure. Neuroimage 2009; 47: 1141-1147.
102. Hutchinson M, Nakamura T, Moeller JR, et al. The metabolic topography of essential blepharospasm: a focal dystonia with general implications. Neurology 2000; 55: 673-677.
103. Asanuma K, Ma Y, Huang C, et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol 2005; 57: 596-600.
104. Carbon M, Niethammer M, Peng S, et al. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology 2009; 72: 2097-2103.
105. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003; 18: 1415-1423.
106. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S. Magnetic resonance imaging of dystonic states. Adv Neurol 1988; 50: 265-275.
107. Meunier S, Lehericy S, Garnero L, Vidailhet M. Dystonia: lessons from brain mapping. Neuroscientist 2003; 9: 76-81.
108. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699-1706.
109. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20: 592-597.
110. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008; 23: 1353-1360.
111. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005; 20: 783-791.
112. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65: 1423-1429.
113. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, De Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007; 78: 264-270.
114. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008; 23: 510-517.
115. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-1951.
116. Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 2005; 65: 765-767.
117. Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 2006; 21: 2240-2243.
118. Albavera-Hernandez C, Rodriguez JM, Idrovo AJ. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 2009; 23: 394-407.
119. Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA 2009; 301: 2316.
120. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008; 28: 3689-3696.
121. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-312.
122. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 2005; 21: 433-438.
123. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009; 15: 224-231.
124. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 2006; 21: 1737-1741.
125. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 2005;CD004900.
126. American Academy of Ophthalmology. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. Ophthalmology 1989;96(Pt 2):37-41.
127. Krauss JK, Yianni J, Loher TJ, Aziz TZ. Deep brain stimulation for dystonia. J Clin Neurophysiol 2004; 21: 18-30.
128. Capelle HH, Krauss JK. Neuromodulation in Dystonia: current Aspects of Deep Brain Stimulation. Neuromodulation 2009; 12: 8-21.
129. National Institute for Health and Clinical Excellence. Deep brain stimulation for tremor and dystonia (ex-cluding Parkinson's disease). (accessed 5/4/2010).
130. Holloway KL, Baron MS, Brown R, Cifu DX, Carne W, Ramakrishnan V. Deep brain stimulation for dystonia: a meta-analysis. Neuromodulation 2006; 9: 253-261.
131. Schrader C, Benecke R, Deuschl G, et al. Tiefe Hirnstimulation bei Dystonie. Empfehlungen der Deutschen Arbeitsgemeinschaft Tiefe Hirnstimulation. Nervenarzt 2009; 80: 656-661.
132. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355: 1978-1990.
133. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352: 459-467.
134. Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord 2006; 21: 692-695.
135. Kiss ZH, Doig-Beyaert K, Eliasziw M, Tsui J, Haffenden A, Suchowersky O. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 2007; 130: 2879-2886.
136. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007; 64: 170-176.
137. Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain 2008; 131: 1895-1902.
138. Pretto TE, Dalvi A, Kang UJ, Penn RD. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 2008; 109: 405-409.
139. Blahak C, Wohrle JC, Capelle HH, et al. Health-related quality of life in segmental dystonia is improved by bilateral pallidal stimulation. J Neurol 2008; 255: 178-182.
140. Mueller J, Skogseid IM, Benecke R, et al. Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord 2008; 23: 131-134.
141. Skogseid IM. Pallidal deep brain stimulation is effective, and improves quality of life in primary segmental and generalized dystonia. Acta Neurol Scand Suppl 2008; 188: 51-55.
142. Tisch S, Zrinzo L, Limousin P, et al. Effect of electrode contact location on clinical efficacy of pallidal deep brain stimulation in primary generalised dystonia. J Neurol Neurosurg Psychiatry 2007; 78: 1314-1319.
143. Alterman RL, Miravite J, Weisz D, Shils JL, Bressman SB, Tagliati M. Sixty Hertz pallidal deep brain stimulation for primary torsion dystonia. Neurology 2007; 69: 681-688.
144. Alterman RL, Shils JL, Miravite J, Tagliati M. Lower stimulation frequency can enhance tolerability and efficacy of pallidal deep brain stimulation for dystonia. Mov Disord 2007; 22: 366-368.
145. Coubes P, Cif L, El Fertit H, et al. Electrical stimulation of the globus pallidus internus in patients with primary generalized dystonia: long-term results. J Neurosurg 2004; 101: 189-194.
146. Krause M, Fogel W, Kloss M, Rasche D, Volkmann J, Tronnier V. Pallidal stimulation for dystonia. Neurosurgery 2004; 55: 1361-1370.
147. Krauss JK, Pohle T, Weber S, Ozdoba C, Burgunder JM. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet 1999; 354: 837-838.
148. Grips E, Blahak C, Capelle HH, et al. Patterns of reoccurrence of segmental dystonia after discontinuation of deep brain stimulation. J Neurol Neurosurg Psychiatry 2007; 78: 318-320.
149. Woehrle JC, Blahak C, Kekelia K, et al. Chronic Deep Brain Stimulation for Segmental Dystonia. Stereotact Funct Neurosurg 2009; 87: 379-384.
150. Sun B, Chen S, Zhan S, Le W, Krahl SE. Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir Suppl 2007; 97: 207-214.
151. Romito LM, Franzini A, Perani D, et al. Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. Neurology 2007; 68: 875-876.
152. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. Lancet 2000; 355: 2220-2221.
153. Egidi M, Franzini A, Marras C, et al. A survey of Italian cases of dystonia treated by deep brain stimulation. J Neurosurg Sci 2007; 51: 153-158.
154. Borggraefe I, Mehrkens JH, Telegravciska M, et al. Bilateral pallidal stimulation in children and adolescents with primary generalized dystonia - Report of six patients and literature-based analysis of predictive outcomes variables. Brain Dev 2010; 32: 223-228.
155. Yianni J, Bain P, Giladi N, et al. Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov Disord 2003; 18: 436-442.
156. Cersosimo MG, Raina GB, Piedimonte F, Antico J, Graff P, Micheli FE. Pallidal surgery for the treatment of primary generalized dystonia: long-term follow-up. Clin Neurol Neurosurg 2008; 110: 145-150.
157. Isaias IU, Alterman RL, Tagliati M. Deep brain stimulation for primary generalized dystonia: long-term outcomes. Arch Neurol 2009; 66: 465-470.
158. Loher TJ, Capelle HH, Kaelin-Lang A, et al. Deep brain stimulation for dystonia: outcome at long-term follow-up. J Neurol 2008; 255: 881-884.
159. Mehrkens JH, Botzel K, Steude U, et al. Long-term efficacy and safety of chronic globus pallidus internus stimulation in different types of primary dystonia. Stereotact Funct Neurosurg 2009; 87: 8-17.
160. Pillon B, Ardouin C, Dujardin K, et al. Preservation of cognitive function in dystonia treated by pallidal stimulation. Neurology 2006; 66: 1556-1558.
161. Krauss JK. Deep brain stimulation for cervical dystonia. J Neurol Neurosurg Psychiatry 2003; 74: 1598.
162. Eltahawy HA, Saint-Cyr J, Poon YY, Moro E, Lang AE, Lozano AM. Pallidal deep brain stimulation in cervical dystonia: clinical outcome in four cases. Can J Neurol Sci 2004; 31: 328-332.
163. Ostrem JL, Marks WJ Jr, Volz MM, Heath SL, Starr PA. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome). Mov Disord 2007; 22: 1885-1891.
164. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8: 709-717.
165. Berman BD, Starr PA, Marks WJ, Ostrem JL. Induction of bradykinesia with pallidal deep brain stimulation in patients with cranial-cervical dystonia. Stereotact Funct Neurosurg 2009; 87: 37-44.
166. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009; 73: 53-58.
167. Jabusch HC, Zschucke D, Schmidt A, Schuele S, Altenmuller E. Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients. Mov Disord 2005; 20: 1623-1626.
168. Candia V, Rosset-Llobet J, Elbert T, Pascual-Leone A. Changing the brain through therapy for musicians' hand dystonia. Ann N Y Acad Sci 2005; 1060: 335-342.
169. McKenzie AL, Goldman S, Barrango C, Shrime M, Wong T, Byl N. Differences in physical characteristics and response to rehabilitation for patients with hand dystonia: musicians' cramp compared to writers' cramp. J Hand Ther 2009; 22: 172-181.
170. Zetterberg L, Halvorsen K, Farnstrand C, Aquilonius SM, Lindmark B. Physiotherapy in cervical dystonia: six experimental single-case studies. Physiother Theory Pract 2008; 24: 275-290.
171. Byl NN, Archer ES, McKenzie A. Focal hand dystonia: effectiveness of a home program of fitness and learning-based sensorimotor and memory training. J Hand Ther 2009; 22: 183-197.
172. Tinazzi M, Farina S, Bhatia K, et al. TENS for the treatment of writer's cramp dystonia: a randomized, placebo-controlled study. Neurology 2005; 64: 1946-1978.
173. Espay AJ, Hung SW, Sanger TD, Moro E, Fox SH, Lang AE. A writing device improves writing in primary writing tremor. Neurology 2005; 64: 1648-1650.